304 related articles for article (PubMed ID: 3097031)
1. Structure and function of human tissue-type plasminogen activator (t-PA).
van Zonneveld AJ; Veerman H; MacDonald ME; van Mourik JA; Pannekoek H
J Cell Biochem; 1986; 32(3):169-78. PubMed ID: 3097031
[TBL] [Abstract][Full Text] [Related]
2. Autonomous functions of structural domains on human tissue-type plasminogen activator.
van Zonneveld AJ; Veerman H; Pannekoek H
Proc Natl Acad Sci U S A; 1986 Jul; 83(13):4670-4. PubMed ID: 3088564
[TBL] [Abstract][Full Text] [Related]
3. Kinetic characterization of tissue-type plasminogen activator (t-PA) and t-PA deletion mutants.
de Vries C; Veerman H; Nesheim ME; Pannekoek H
Thromb Haemost; 1991 Mar; 65(3):280-5. PubMed ID: 1904654
[TBL] [Abstract][Full Text] [Related]
4. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
[TBL] [Abstract][Full Text] [Related]
5. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
6. [Expression and activity of tissue-type plasminogen activator mutant reteplase with deletion of PAI-1 binding sites].
Zhu MC; Zhan Z; Wang YJ; Liu CG; Shi Y; Cai Q
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Sep; 21(5):565-9. PubMed ID: 16143058
[TBL] [Abstract][Full Text] [Related]
7. Fibrin affinity and clearance of t-PA deletion and substitution analogues.
Johannessen M; Diness V; Pingel K; Petersen LC; Rao D; Lioubin P; O'Hara P; Mulvihill E
Thromb Haemost; 1990 Feb; 63(1):54-9. PubMed ID: 2111048
[TBL] [Abstract][Full Text] [Related]
8. Mapping of epitopes on human tissue-type plasminogen activator with recombinant deletion mutant proteins.
van Zonneveld AJ; Veerman H; Brakenhoff JP; Aarden LA; Cajot JF; Pannekoek H
Thromb Haemost; 1987 Feb; 57(1):82-6. PubMed ID: 2438798
[TBL] [Abstract][Full Text] [Related]
9. Serpin-resistant mutants of human tissue-type plasminogen activator.
Madison EL; Goldsmith EJ; Gerard RD; Gething MJ; Sambrook JF
Nature; 1989 Jun; 339(6227):721-4. PubMed ID: 2500599
[TBL] [Abstract][Full Text] [Related]
10. The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator.
Lamba D; Bauer M; Huber R; Fischer S; Rudolph R; Kohnert U; Bode W
J Mol Biol; 1996 Apr; 258(1):117-35. PubMed ID: 8613982
[TBL] [Abstract][Full Text] [Related]
11. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
12. Determinants of induction of increased synthesis of plasminogen activator inhibitor type-1 in human endothelial cells by t-PA.
Fujii S; Sobel BE
Thromb Haemost; 1992 Feb; 67(2):233-8. PubMed ID: 1621243
[TBL] [Abstract][Full Text] [Related]
13. Relationships between structure and function of tissue-type plasminogen activator.
Rijken DC
Klin Wochenschr; 1988; 66 Suppl 12():33-9. PubMed ID: 3126346
[TBL] [Abstract][Full Text] [Related]
14. The effector roles of kringle 1 and kringle 2 in the enzymatic properties of recombinant tissue-type plasminogen activator as revealed by generation of recombinant molecules containing each kringle linked to the protease domain.
Rydzewski A; Castellino FJ
Arch Biochem Biophys; 1993 Jan; 300(1):472-82. PubMed ID: 8424682
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line.
Lijnen HR; Webb PD; Van Hoef B; De Cock F; Stassen JM; Prior SD; Collen D
Thromb Haemost; 1992 Feb; 67(2):239-47. PubMed ID: 1621244
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor-1 is the primary inhibitor of tissue-type plasminogen activator in pregnancy plasma.
Jørgensen M; Philips M; Thorsen S; Selmer J; Zeuthen J
Thromb Haemost; 1987 Oct; 58(3):872-8. PubMed ID: 3124286
[TBL] [Abstract][Full Text] [Related]
17. Characterization of human tissue-type plasminogen activator variants with amino acid mutations in the kringle 1 domain.
Ikenaka Y; Yajima K; Yahara H; Maruyama H; Matsumoto K; Okada K; Ueshima S; Matsuo O
Blood Coagul Fibrinolysis; 1992 Aug; 3(4):381-7. PubMed ID: 1330023
[TBL] [Abstract][Full Text] [Related]
18. Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the fibronectin finger-like domain and the kringle 1 domain.
Yahara H; Matsumoto K; Maruyama H; Nagaoka T; Ikenaka Y; Yajima K; Fukao H; Ueshima S; Matsuo O
Thromb Haemost; 1994 Dec; 72(6):893-9. PubMed ID: 7740460
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
J Biol Chem; 1990 Apr; 265(10):5677-83. PubMed ID: 2156824
[TBL] [Abstract][Full Text] [Related]
20. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
